134 related articles for article (PubMed ID: 11931623)
1. Synthesis and biological characterization of L-N(6)-(1-iminoethyl)lysine 5-tetrazole-amide, a prodrug of a selective iNOS inhibitor.
Hallinan EA; Tsymbalov S; Dorn CR; Pitzele BS; Hansen DW; Moore WM; Jerome GM; Connor JR; Branson LF; Widomski DL; Zhang Y; Currie MG; Manning PT
J Med Chem; 2002 Apr; 45(8):1686-9. PubMed ID: 11931623
[TBL] [Abstract][Full Text] [Related]
2. A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics.
Hansel TT; Kharitonov SA; Donnelly LE; Erin EM; Currie MG; Moore WM; Manning PT; Recker DP; Barnes PJ
FASEB J; 2003 Jul; 17(10):1298-300. PubMed ID: 12738811
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of inducible nitric oxide synthase exacerbates erosive joint disease.
McCartney-Francis NL; Song X; Mizel DE; Wahl SM
J Immunol; 2001 Feb; 166(4):2734-40. PubMed ID: 11160339
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the effects of L-NAME, 7-NI and L-NIL on carrageenan-induced hindpaw oedema and NOS activity.
Handy RL; Moore PK
Br J Pharmacol; 1998 Mar; 123(6):1119-26. PubMed ID: 9559895
[TBL] [Abstract][Full Text] [Related]
5. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
6. A prodrug of a selective inhibitor of inducible nitric oxide synthase is neuroprotective in the rat model of glaucoma.
Neufeld AH; Das S; Vora S; Gachie E; Kawai S; Manning PT; Connor JR
J Glaucoma; 2002 Jun; 11(3):221-5. PubMed ID: 12140399
[TBL] [Abstract][Full Text] [Related]
7. Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw inflammation.
Salvemini D; Wang ZQ; Wyatt PS; Bourdon DM; Marino MH; Manning PT; Currie MG
Br J Pharmacol; 1996 Jun; 118(4):829-38. PubMed ID: 8799551
[TBL] [Abstract][Full Text] [Related]
8. Divergent roles of nitrergic and prostanoid pathways in chronic joint inflammation.
Day SM; Lockhart JC; Ferrell WR; McLean JS
Ann Rheum Dis; 2004 Dec; 63(12):1564-70. PubMed ID: 15547079
[TBL] [Abstract][Full Text] [Related]
9. Selective iNOS inhibition attenuates acetylcholine- and bradykinin-induced vasoconstriction in lipopolysaccharide-exposed rat lungs.
Fischer LG; Horstman DJ; Hahnenkamp K; Kechner NE; Rich GF
Anesthesiology; 1999 Dec; 91(6):1724-32. PubMed ID: 10598616
[TBL] [Abstract][Full Text] [Related]
10. Time-dependent aggravation or attenuation of lipopolysaccharide-induced gastric injury by nitric oxide synthase inhibition.
Suliburk JW; Helmer KS; Kennison SD; Mercer DW; Robinson EK
J Surg Res; 2005 Dec; 129(2):265-71. PubMed ID: 16026802
[TBL] [Abstract][Full Text] [Related]
11. Disposition and pharmacokinetics of L-N6-(1-iminoethyl)lysine-5-tetrazole-amide, a selective iNOS inhibitor, in rats.
Zhang JY; Wang Y; Milton MN; Kraus L; Breau AP; Paulson SK
J Pharm Sci; 2004 May; 93(5):1229-40. PubMed ID: 15067699
[TBL] [Abstract][Full Text] [Related]
12. Selective inducible nitric oxide synthase (iNOS) inhibition attenuates remote acute lung injury in a model of ruptured abdominal aortic aneurysm.
Harkin DW; Rubin BB; Romaschin A; Lindsay TF
J Surg Res; 2004 Aug; 120(2):230-41. PubMed ID: 15234218
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of inducible nitric oxide synthase enhances intraglomerular coagulation in chronic anti-Thy 1 nephritis.
Westenfeld R; Gawlik A; de Heer E; Kitahara M; Abou-Rebyeh F; Floege J; Ketteler M
Kidney Int; 2002 Mar; 61(3):834-8. PubMed ID: 11849434
[TBL] [Abstract][Full Text] [Related]
14. Selective iNOS inhibition prevents hypotension in septic rats while preserving endothelium-dependent vasodilation.
Strunk V; Hahnenkamp K; Schneuing M; Fischer LG; Rich GF
Anesth Analg; 2001 Mar; 92(3):681-7. PubMed ID: 11226101
[TBL] [Abstract][Full Text] [Related]
15. Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase.
Pelletier JP; Jovanovic D; Fernandes JC; Manning P; Connor JR; Currie MG; Di Battista JA; Martel-Pelletier J
Arthritis Rheum; 1998 Jul; 41(7):1275-86. PubMed ID: 9663486
[TBL] [Abstract][Full Text] [Related]
16. Effect of chronic treatment with the inducible nitric oxide synthase inhibitor N-iminoethyl-L-lysine or with L-arginine on progression of coronary and aortic atherosclerosis in hypercholesterolemic rabbits.
Behr-Roussel D; Rupin A; Simonet S; Bonhomme E; Coumailleau S; Cordi A; Serkiz B; Fabiani JN; Verbeuren TJ
Circulation; 2000 Aug; 102(9):1033-8. PubMed ID: 10961969
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of inducible nitric oxide synthase in persistent pain.
Budziñski M; Misterek K; Gumulka W; Dorociak A
Life Sci; 2000; 66(4):301-5. PubMed ID: 10665981
[TBL] [Abstract][Full Text] [Related]
18. Inducible NOS inhibition, eicosapentaenoic acid supplementation, and angiotensin II-induced renal damage.
Theuer J; Shagdarsuren E; Muller DN; Kaergel E; Honeck H; Park JK; Fiebeler A; Dechend R; Haller H; Luft FC; Schunck WH
Kidney Int; 2005 Jan; 67(1):248-58. PubMed ID: 15610248
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of inducible nitric oxide synthase reduces renal ischemia/reperfusion injury.
Chatterjee PK; Patel NS; Kvale EO; Cuzzocrea S; Brown PA; Stewart KN; Mota-Filipe H; Thiemermann C
Kidney Int; 2002 Mar; 61(3):862-71. PubMed ID: 11849439
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of inducible nitric oxide synthase inactivation by aminoguanidine and L-N6-(1-iminoethyl)lysine.
Bryk R; Wolff DJ
Biochemistry; 1998 Apr; 37(14):4844-52. PubMed ID: 9538001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
